Table 2

Clinical and serological characteristics of patients with RA and SpA

Patients	Age	Sex	DMARD	Disease duration	CRP	RF	HLA-B27
Patients	Age	Sex	DMARD	(months)	(mg/l )*	(IU/ml)*	HLA-B27
DMARD, disease modifying antirheumatic drug; SSZ, sulfasalazine; Pred, prednisolone; IM gold, intramuscular gold; MTX, methotrexate; CyA, ciclosporin A; NSAID, non-steroidal anti-inflammatory drug; uSpA, undifferentiated spondyloarthritis; PsA, psoriatic arthritis; AS, ankylosing spondyloarthritis; N/A, not applicable.
*CRP, normal <60 mg/l; RF, normal <20 IU/ml.
1RA	60	M	SSZ, Pred,	132	17	248	N/A
2RA	74	M	IM gold, MTX	>12	5	101	N/A
3RA	36	F	CyA, Pred, NSAID	156	3	80	N/A
4RA	63	F	NSAID	<12	<1	<20	N/A
5RA	71	M	Nil	3	120	1220	N/A
6RA	59	F	MTX, SSZ	216	35	531	N/A
7RA	41	F	Nil	6	<1	26	N/A
8RA	74	F	Nil	24	9	1552	N/A
9RA	48	F	Nil	<12	8	335	N/A
10RA	84	M	MTX, Pred	84	90	<20	Negative
11uSpA	27	F	Depomedrol	12	6	N/A	Negative
12PsA	59	F	SSZ (2 days), Pred	96	164	N/A	Negative
13uSpA	42	F	Nil	>60	16	N/A	Negative
14PsA	49	F	Allopurinol, NSAID	60	45	N/A	Negative
15PsA	64	M	MTX	>12	48	N/A	Negative
16AS	50	M	SSZ, NSAID	384	34	N/A	positive
17PsA	58	M	NSAID	>12	6	N/A	Negative
18uSpA	33	M	NSAID	>12	26	N/A	Positive
19uSpA	27	F	NSAID	24	3	N/A	Positive
20uSpA	82	M	NSAID	6	384	N/A	Positive